Laduviglusib dihydrochloride

Cat. No.:	HY-10182C
CAS No.:	2109414-84-6
Molecular Formula:	$C_{22}H_{20}Cl_4N_8$
Molecular Weight:	538.26
Target:	GSK-3; β-catenin; Wnt
Pathway:	PI3K/Akt/mTOR; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Laduviglusib;CHIR 99021;CHIR99021;CHIR-99021;CT99021;CT 99021;CT-99021
IC_{50} & Target	IC50: 10 nM/6.7 nM (GSK-3α/β)[1]

CUSTOMER VALIDATION

- Nat Med. 2016 May;22(5):547-56.
- Cell Discov. 2023 Jun 6;9(1):53.
- Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.
- Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8.
- Mil Med Res. 2020 Sep 6;7(1):42.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.

[2]. Ye S, et al. Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embryonic stem cells from refractory mouse strains. PLoS One. 2012;7(4):e35892.

[3]. Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA